Skip to main content
ARVN
NASDAQ Life Sciences

FDA Approves First-Ever PROTAC Drug VEPPANU for Advanced Breast Cancer, a Major Win for Arvinas

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.27
Mkt Cap
$656.879M
52W Low
$5.9
52W High
$14.51
52W Position info
74% above low
Off High info
29% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ARVN sits 74% above its 52-week low of $5.9 on light trading volume (0.3× avg).

Summary

The FDA has granted accelerated approval for Arvinas's VEPPANU (vepdegestrant) for the treatment of ESR1-mutated, ER+/HER2- advanced breast cancer. This marks a transformative milestone as VEPPANU is the first-ever FDA-approved PROteolysis TArgeting Chimera (PROTAC) therapy, validating Arvinas's pioneering technology. The approval was received ahead of the PDUFA date of June 5, 2026, indicating a strong regulatory outcome. This development is highly significant for Arvinas, representing its first approved medicine and opening a new revenue stream in partnership with Pfizer Inc., which co-developed the drug. The drug addresses a significant unmet medical need for patients who have progressed on prior endocrine therapy. Investors will now focus on the commercialization strategy and the selection of a third party to bring the treatment to market, as well as the implications for Arvinas's broader PROTAC pipeline.

At the time of this announcement, ARVN was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $656.9M. The 52-week trading range was $5.90 to $14.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ARVN - Latest Insights

ARVN
Oct 07, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.52
Real-time Price: $7.86 info
Change: +$0.340 (+5%) info
Market Cap: $513.935M info
ARVN
Sep 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.60
Real-time Price: $7.86 info
Change: +$0.260 (+3%) info
Market Cap: $513.935M info
ARVN
Aug 04, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $9.00
Real-time Price: $7.86 info
Change: -$1.14 (-13%) info
Market Cap: $513.935M info
ARVN
Aug 04, 2026, 7:02 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $7.86 info
Change: -$0.570 (-7%) info
Market Cap: $513.935M info
ARVN
Jun 22, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.74
Real-time Price: $7.86 info
Change: +$0.120 (+2%) info
Market Cap: $513.935M info